Vir Biotechnology, Inc. Common Stock

VIR trades at a compelling 52.1 RSI—perfectly centered and signaling neither overbought nor oversold conditions—yet carries a notably elevated 10.11% short float, suggesting meaningful skepticism from bearish traders. With a $1.6B market cap and no P/E ratio (indicating pre-profitability or recent losses), the stock appears to be a clinical-stage biotech where sentiment rather than earnings drives valuation. The absence of a 52-week high and substantial short positioning creates potential squeeze dynamics if positive trial data or partnership news emerges, though the lack of traditional valuation metrics makes it inherently speculative and illiquid relative to larger therapeutics peers.